The Office Building of the International Biopharmaceutical Company Astrazeneca.
Cfoto | Future publication | Getty images
A version of this article appeared for the first time in the Healthy Bulletin returns from CNBC, which brings the latest medical care news directly to its entrance tray. Subscribe here To receive future editions.
President Donald Trump has been pressing pharmaceutical companies to reduce drug costs of the United States, and may be starting to work, at least in Astrazeneca.
Astrazeneca has proposed price cuts to certain drugs in the United States, said its CEO Pascal Soriot to journalists on Tuesday, after the company's income and profits exceeded estimates.
“We have made proposals of what we, as a company, believe that it could be done, which would actually imply a rebalancing price with a reduction in the United States,” said Soriot, while noting that price dynamics in the country is “very complicated” and lack transparency.
He said the Trump administration is reviewing the company's proposals, but did not specify what treatments included. Astrazeneca seems to be among the first drug addicts in revealing that he has presented price cuts to the Trump administration.
“I think it is necessary to rebalance prices worldwide. The United States can no longer pay the I + D of the world,” said Pascal.
“We definitely support the idea of rebuilding with some reduction in price levels in the United States, and some increase, we are not talking about mass increases, in Europe,” he continued.
The company previously established the objective of reaching $ 80 billion in sales for the end of the decade, with 50% of that, or approximately $ 40 billion, scheduled for the United States.
Why now?
Soriot's comments are produced two months after Trump signed a broad executive order that aims to renew a plan to reduce the costs of medicines in the United States by linking prices with the lowest in other developed countries. Trump has described the effort, called the policy of the “most favored nation”, as “equalization” prices.
Nor can we forget the president's planned rates on the imported pharmaceutical products to the US. Taxes aim to boost domestic drug manufacturing, even after Astrazeneca and other companies have announced billions of dollars in new investments in the United States in recent months.
Astrazeneca last week said he plans to invest $ 50 billion in strengthening his manufacturing and research capabilities in the United States by 2030, which includes new sites and expansions of previous investments.
Also on Tuesday, Soriot said that he hopes that all Astrazeneca medications for American patients be produced locally in a few months.
He added that the company is considering selling some medications to patients directly, a measure to which companies such as Eli Lilly, Novo Nordisk, Pfizer and Bristol Myers Squibb have adopted as patients fight to pay medications in the United States.
“We want to behave in the United States as an American company,” said Soriot.
But he added that Astrazeneca based in the United Kingdom is “committed” to his country of origin, which occurs amid reports that the company is considering changing its list in the United States.
Pascal refused to comment on rumors about the company's second quarter -quarter calls.
Do not hesitate to send any advice, suggestion, stories ideas and data to Annika in [email protected].
The latest in Medical Care Technology: Daxxity enters the competitive market scribes with a new free offer
Daxxity announced a new tool last week called Daxxity Scribe, a free artificial intelligence documentation solution that aims to help doctors reduce the time they spend on paperwork.
The company is the last to immerse yourself in the writer market of the fiercely competitive, which has taken off as medical care executives seek ways to reduce the exhaustion of personnel and discouraging administrative workloads.
Like other tools in the market, Daxxity Scribe uses AI to write clinical notes in real time as doctors record their visits with the patient's permission. But by offering the tool for free, Daxxity is adopting a different approach to its competitors such as Microsoft, Open and others.
“Comparable scribes services can cost hundreds of dollars per user per month,” said Dxxxity in a statement. “We believe that powerful tools like this should be accessible to all doctors, not only for those with budgets.”
Daxxity is a digital platform for medical professionals that helps doctors to keep up with medical news, administer paperwork, find references and carry out telesalud appointments with patients. The company mainly generates income through its contracting solutions and marketing offers for customers such as pharmaceutical companies.
In addition to Daxxity Scribe, the company also offers doctors a call tool Dxxxity GPT and a video and telesalud platform called Dialer Dialer for free. In other words, he has followed this play book before.
But while the free offer will probably attract many doctors, it may not yet put the market at the head.
Several other players in space, including Microsoft and Abridge, can withstand deep integrations with electronic health records, while Daxxity Scribe is starting with a beta integration with its own product, Daxxity Dialer. Similarly, users of the maximum decade can choose between structured or notes freely, but other suppliers offer specific support for the specialty of a supplier, as well as additional characteristics for coding and billing.
As a result, large and complex health systems will probably be willing to pay for the scribes of AI, at least for now.
Daxxity said he will extend his scribe in the coming months, and doctors can register for early access.
Read the full announcement here.
Do not hesitate to send any advice, suggestion, stories ideas and data to Ashley at [email protected].
